Abu Dhabi, United Arab Emirates
+919405476170
+919405476170
ANTI CANCER MEDICINE

Sigrima 420mg Injection (Pertuzumab) — Ernest Oncology India — Global Exporter | Supply to USA, UK, UAE, Australia, Singapore, Africa & Asia

In stock•cod not available
Phone Number

+919405476170

Mon-Thu: 10 AM - 2 PM • Fri: 3 PM - 7AM

Other Website Visit our other website
Address Abu Dhabi , Abu Dhabi Region , Abu Dhabi

Abu Dhabi, United Arab Emirates, United Arab Emirates, 1

Description

Sigrima 420mg Injection (Pertuzumab): Global B2B Procurement and SEO Clinical Guide In the modern oncology landscape, Sigrima 420mg (Pertuzumab) is a pivotal targeted therapy for HER2-positive breast cancer. For healthcare providers, hospitals, and pharmaceutical wholesalers across the USA, UK, UAE, Australia, Singapore, South Africa, Europe, the Middle East, Africa, and Asia, establishing a reliable supply of this monoclonal antibody is essential for improving patient survival rates. As a premier pharmaceutical exporter from India, Ernest Oncology (a division of Ernest Pharmaceutical Pvt. Ltd.) provides high-standard global distribution for Sigrima 420mg. This 3000-word authority guide covers the clinical data, preparation protocols, and international supply chain logistics required for professional medical procurement. 1.1 Understanding Sigrima (Pertuzumab) Sigrima is a biosimilar of Pertuzumab, a recombinant humanized monoclonal antibody. It is specifically engineered to target the Human Epidermal Growth Factor Receptor 2 (HER2) protein, which is overexpressed in approximately 20% of breast cancer cases. 1.2 Mechanism of Action: Dimerization Inhibition Unlike other HER2-targeted therapies that simply bind to the receptor, Sigrima works through a unique process called dimerization inhibition: Targeting Subdomain II: Sigrima binds specifically to the extracellular dimerization domain (Subdomain II) of the HER2 protein. Blocking the Pairing: It prevents HER2 from pairing (dimerizing) with other HER family receptors, such as HER3. Signaling Shutdown: By blocking this pairing, Sigrima shuts down the intracellular signaling pathways that drive uncontrolled cancer cell growth and survival. ADCC Activation: Sigrima also triggers Antibody-Dependent Cell-Mediated Cytotoxicity (ADCC), where the body’s immune system is recruited to attack and destroy the cancer cells. Adjuvant Treatment (Post-Surgery) Administered after surgery for patients with early-stage HER2-positive breast cancer who are at high risk of recurrence, ensuring that microscopic remaining cancer cells are eliminated. Part 3: Administration, Dosage, and Preparation 3.1 Recommended Dosage Schedule Sigrima is administered via intravenous (IV) infusion every 3 weeks: Initial Loading Dose: 840 mg (two 420 mg vials) administered as a 60-minute infusion. Maintenance Dose: 420 mg (one vial) administered every 3 weeks as a 30- to 60-minute infusion. 3.2 Preparation and Dilution Protocols Inspection: The 14 ml vial should be a clear to slightly opalescent, colorless to pale brown solution. Dilution: Withdraw the required volume from the vial and add it to a 250 ml PVC or non-PVC polyolefin infusion bag containing 0.9% Sodium Chloride (Normal Saline). Important: Do NOT use Dextrose (5%) solution, as it is chemically incompatible with Sigrima. Mixing: Gently invert the bag to mix. Do not shake, as this may denature the protein. Part 4: Safety, Side Effects, and Monitoring 4.1 Cardiac Function Monitoring Sigrima, especially when used with other anti-HER2 agents, can affect the heart. LVEF Assessment: Left Ventricular Ejection Fraction (LVEF) must be measured via echocardiogram or MUGA scan before starting treatment and every 3–6 months during therapy. 4.2 Embryo-Fetal Toxicity Sigrima can cause fetal harm or death. It is strictly contraindicated during pregnancy. Females of reproductive potential must use effective contraception during treatment and for 7 months after the final dose. 4.3 Common Adverse Reactions Diarrhea (often managed with anti-diarrheals) Alopecia (hair loss) Neutropenia (low white blood cell count) Nausea and Fatigue Infusion-related reactions (fever, chills) We facilitate smooth customs clearance in Singapore, Australia, and the UAE by providing: Certificate of Analysis (COA) WHO-GMP and ISO 9001:2015 Certifications Valid Export Permits and Customs Invoices Batch-specific stability data Contact Ernest Oncology — Leading Pharmaceutical Exporter from India 📞 Order & Inquiry Details [GROUP OF ERNEST PHARMACEUTICAL PVT. LTD] 🌐 Websites www.oncologymediciensupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email exports@ernestpharmaceuticals.com 📦 Business Type Exporter | Bulk Supplier | Distributor 📲 WhatsApp +91 93599 02383 🔗 https://wa.me/919359902383

Keywords

Other Products

view all

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

About Imatinib Mesylate Tablets Imatinib Mesylate Tablets are prescription oncology medicines belonging to the tyrosine kinase inhibitor (TKI) class. They are widely used in specialized oncology and hematology treatment programs under the supervision of qualified medical professionals. The tablets are manufactured following stringent pharmaceutical quality standards and supplied to regulated healthcare markets through licensed distribution networks. Product Profile Specification: Information Generic Name: Imatinib Mesylate Dosage Form: Oral Tablets Available Strengths: 100 mg & 400 mg Therapeutic Category: Oncology Medicine Drug Class: :Tyrosine Kinase Inhibitor (TKI) Prescription Status: Prescription Only Country of Origin: India Medical Applications: Hematology treatment programs Oncology management protocols Long-term physician-supervised therapy Hospital cancer care services Specialized oncology clinics Clinical treatment pathways Safety & Clinical Guidance: Use the medicine only under medical supervision. Attend scheduled follow-up appointments. Inform healthcare providers about existing medical conditions and concurrent medications. Follow laboratory monitoring recommendations when advised. Report unusual symptoms promptly to the treating physician. Why Choose Our Pharmaceutical Export Services: Consistent international product availability Bulk supply for institutional buyers Experienced pharmaceutical export team Timely worldwide dispatch Complete export documentation support Quality-focused sourcing network Competitive commercial pricing Regulatory & Export Documentation Certificate of Analysis (COA) Certificate of Origin (COO) Commercial Invoice Packing List Batch Certificate Product Specification Sheet Manufacturing Compliance Docum Imatinib Mesylate Tablets 100 mg Imatinib Mesylate Tablets 400 mg Dasatinib Tablets Nilotinib Capsules Bosutinib Tablets Ponatinib Tablets Erlotinib Tablets Gefitinib Tablets Frequently Asked Questions 1. Which strengths of Imatinib Mesylate Tablets are available for export? The commonly supplied strengths are 100 mg and 400 mg, subject to manufacturer availability and destination market requirements. 2. Who can place bulk orders for Imatinib Mesylate Tablets? Licensed pharmaceutical importers, hospitals, oncology distributors, government procurement agencies, and authorized healthcare wholesalers can procure bulk quantities. 3. Are export documents provided with international shipments? Yes. Eligible orders can be accompanied by COA, COO, CPP (where applicable), commercial invoices, packing lists, batch documentation, and other required regulatory documents. 4. Which countries frequently source Imatinib Mesylate Tablets? Demand is strong in the United States (Washington, D.C.), United Kingdom (London), Australia (Canberra), Canada (Ottawa), Singapore, France (Paris), Germany (Berlin), UAE (Abu Dhabi), Saudi Arabia (Riyadh), South Africa (Pretoria), and Nigeria (Abuja). 5. Why do global healthcare buyers choose Indian exporters for Imatinib Mesylate Tablets? Indian pharmaceutical exporters are recognized for supplying quality-assured oncology medicines, dependable bulk availability, competitive commercial pricing, regulatory documentation support, and efficient worldwide distribution tailored to institutional healthcare procurement. #ImatinibMesylate #Imatinib100mg #Imatinib400mg #TyrosineKinaseInhibitor #TargetedTherapy #OncologyMedicine #CancerCare #PharmaceuticalExporter #WholesaleMedicines #HospitalPharmacy #MedicineSupplier #IndianPharma #BulkMedicine #HealthcareDistributor #GlobalHealthcare #MedicalImports #OncologyExport #HealthcareProcurement #CancerMedicineSupplier #ErnestPharmaceutical Online Imatinib Mesylate Tablets Imatinib Mesylate Tablets Supplier India Wholesale Imatinib Tablets Buy Imatinib 100 mg Tablets Imatinib 400 mg Tablet Exporter Tyrosine Kinase Inhibitor Supplier Oncology Tablet Export Company Bulk Cancer Medicine Supplier Pharmaceutical Exporter India 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Trusted Irinotecan Hydrochloride Injection Supplier from India for Global Pharmaceutical Distribution Irinotecan Hydrochloride Injection USP 20 mg/mL is a sterile prescription oncology medicine classified as a topoisomerase I inhibitor. It is administered by oncology specialists as part of carefully planned chemotherapy protocols in hospital and cancer treatment facilities. Every dose is prepared and infused under controlled clinical conditions to ensure safe administration and patient monitoring. Produced under internationally recognized manufacturing standards, this injectable medicine is supplied to regulated pharmaceutical markets through reliable global export channels. Medical Applications: Colorectal oncology care Gastrointestinal cancer management Advanced oncology treatment Combination chemotherapy protocols Hospital-based cancer therapy Specialist oncology services Safety, Handling & Regulatory Compliance: Irinotecan Injection should be prepared and administered by trained oncology personnel following institutional handling procedures. International shipments can be supported with GMP documentation, quality certificates, batch records, and regulatory documents required by destination markets. Administration Information: This injection is administered by qualified healthcare professionals through intravenous infusion in hospitals or oncology centres. The treatment schedule and dosage are determined according to the patient's clinical condition and approved chemotherapy protocol. Export Documentation Certificate of Analysis (COA) Certificate of Origin (COO) Certificate of Pharmaceutical Product (CPP) (where applicable) GMP Certificate Commercial Invoice Packing List Batch Manufacturing Documents Product Specification Sheet Worldwide Procurement of Injectable Oncology Medicines Continues to Expand The growing demand for advanced cancer treatment has increased procurement of injectable oncology medicines across international healthcare systems. Buyers from hospitals and pharmaceutical distribution companies continue seeking dependable exporters capable of delivering regulatory-compliant products, uninterrupted supply, and efficient worldwide logistics. Oxaliplatin Injection Fluorouracil Injection Leucovorin Calcium Injection Capecitabine Tablets Bevacizumab Injection Cetuximab Injection Gemcitabine Injection Frequently Asked Questions 1. Which strength of Irinotecan Injection is available for export? Irinotecan Hydrochloride Injection USP is commonly supplied as 20 mg/mL, with multiple vial presentations available depending on manufacturer specifications. 2. Who can purchase Irinotecan Injection in bulk? Licensed hospitals, oncology centres, pharmaceutical distributors, government procurement agencies, and authorized importers can place wholesale orders. 3. Is export documentation provided with international shipments? Yes. Eligible shipments may include COA, COO, GMP certificates, CPP (where applicable), commercial invoices, packing lists, and batch documentation. 4. Which countries frequently import Irinotecan Hydrochloride Injection? Major demand comes from the United States (Washington, D.C.), United Kingdom (London), Australia (Canberra), Canada (Ottawa), France (Paris), Germany (Berlin), Singapore, UAE (Abu Dhabi), Saudi Arabia (Riyadh), South Africa (Pretoria), and Nigeria (Abuja). 5. Why do international healthcare buyers source Irinotecan Injection from India? Indian pharmaceutical exporters are recognized for dependable manufacturing quality, strong export capabilities, regulatory documentation support, competitive commercial pricing, and reliable supply solutions for hospitals and healthcare distributors worldwide. Buy Irinotecan Hydrochloride Injection Online Irinotecan Injection USP 20 mg/mL Supplier Wholesale Irinotecan Injection Topoisomerase Inhibitor Supplier Oncology Injection Export Company Bulk Cancer Injection Supplier Injectable Oncology Medicine Export Pharmaceutical Exporter India 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1 #IrinotecanInjection #IrinotecanHydrochloride #OncologyInjection #CancerMedicine #Chemotherapy #InjectableMedicines #TopoisomeraseInhibitor #HospitalPharmacy #PharmaceuticalExporter #MedicineSupplier #IndianPharma #BulkMedicine #HealthcareDistributor #GlobalPharma #CancerCare #MedicalImports #OncologyExport #HospitalProcurement #WorldwideHealthcare #ErnestPharmaceutical

68179d65be22ee500d53ff54 Card 2

product image
ANTI CANCER MEDICINE

Ifosfamide Injection (500 mg, 1 g, 2 g) is a widely used cytotoxic medicine from the oxazaphosphorine group, indicated mainly for solid tumors and hematologic malignancies. Key strengths for procurement pages Ifosfamide Injection 500 mg Ifosfamide Injection 1 g Ifosfamide Injection 2 g Dosage forms: single‑dose vials, multi‑strength portfolio (500 mg, 1 g, 2 g) Typical pack configuration: 1 vial per carton, export‑grade secondary packaging Stability and transport: controlled temperature, light‑protected, compliant with standard cold‑chain or ambient logistics according to product specification Provide detailed specification sheets and COAs for regulatory authorities and institutional buyers to support product registration and tender submissions. Indications and Clinical Use Ifosfamide Injection is used in combination chemotherapy regimens for various malignancies, typically in specialist oncology units. As this is a YMYL (Your Money Your Life) pharmaceutical topic, content for public sites should stay informational and avoid therapeutic claims beyond approved labels. Safety, Handling, and Regulatory Compliance Ifosfamide Injection is intended for handling by trained oncology professionals using established safety procedures. International supplies are supported with quality certifications and export documentation based on destination country requirements. Product Specifications Feature Description Generic Name Ifosfamide Dosage Form Sterile Powder for Injection Available Strengths 500 mg, 1 g, 2 g Therapeutic Class Anticancer Medicine Drug Category Alkylating Agent Route Intravenous Administration Prescription Status Hospital Prescription Only Supply Type Bulk Supply & International Export Country of Origin India Clinical Uses: -Soft tissue sarcoma treatment protocols -Bone cancer management -Testicular cancer therapy -Lymphoma treatment plans -Advanced oncology care -Multi-drug chemotherapy programs Wholesale Ifosfamide Injection Supplier Ifosfamide 500 mg for Hospital Procurement Ifosfamide Injection 1 g Bulk Distributor Ifosfamide 2 g Global Pharmaceutical Supply Trusted Oncology Injectable Exporter Cancer Care Injection Supplier Worldwide Sterile Ifosfamide Injection Manufacturer Ifosfamide Oncology Medicine Distributor Bulk Chemotherapy Injection Supplier 🏥 Your Trusted Global Partner for Oncology Pharmaceuticals [GROUP OF ERNEST PHARMACEUTICALS PVT. LTD.] 🌐 Websites: www.oncologymedicinesupplier.com www.ernestimpex.com www.ernestvision.com 📧 Email: exports@ernestpharmaceuticals.com 📦 Business Type: Export • Distribution • Bulk Supply 📲 WhatsApp: +91 9405476170 https://wa.me/message/V2MEXZ6ZAYY5B1 Frequently Asked Questions 1. Is Ifosfamide Injection supplied for international hospital procurement? Yes. Bulk quantities are available for licensed hospitals, oncology distributors, pharmaceutical importers, and government healthcare organizations. 2. Which strengths of Ifosfamide Injection are available? The commonly supplied strengths include 500 mg, 1 g, and 2 g, depending on manufacturer availability and destination market requirements. 3. How is Ifosfamide Injection administered? It is administered intravenously by qualified healthcare professionals in specialized oncology or hospital settings according to prescribed chemotherapy protocols. 4. What export documents are provided with international orders? Eligible shipments may include COA, COO, CPP (where applicable), commercial invoice, packing list, batch documents, and other regulatory paperwork required by the importing country. 5. Why do international buyers choose Indian exporters for Ifosfamide Injection? Indian pharmaceutical exporters are valued for their ability to provide consistent bulk availability, internationally accepted manufacturing standards, responsive export support, and efficient global distribution networks. This enables hospitals, oncology distributors, and licensed importers to maintain a dependable supply of quality injectable medicines while meeting their procurement and regulatory requirements. Cyclophosphamide Injection Doxorubicin Injection Cisplatin Injection Carboplatin Injection Gemcitabine Injection Etoposide Injection